www.nanoviricides.com
NanoViricides, Inc. is a nano-biopharmaceutical company whose business goals are to discover, develop and commercialize therapeutics (nanoviricides™) to advance the care of patients suffering from life-threatening viral infections.
NanoViricides Articles and News
Archive-
22/05/2013
NanoViricides reports stronger cash position; sufficient for first clinical trials
NanoViricides (OTCBB:NNVC), a development stage company creating special purpose nanomaterials for antiviral therapy, said Wednesday its cash position at the end of the first quarter was "sufficient to carry out its initial clinical trials of its first drug candidate."
-
-
-
-
06/03/2013
NanoViricides shares gain as it takes the lead at two sessions for the Symposium on Nanomedicines
NanoViricides (OTCBB:NNVC) saw its shares surge over seven per cent Wednesday, after announcing that president Anil Diwan will lead section 1 of the Symposium on Nanomedicines: Charting a Roadmap to Commercialization, called “Designing Nanomedicines”.
-
28/02/2013
NanoViricides armed with $18 mln of cash after retirement of Series C preferred stock
NanoViricides (OTCBB: NNVC) says it has retired the remainder of its Series C convertible preferred stock previously purchased by Seaside 88 with a cash payment, and said it holds around $18 million of cash in hand following the transaction.
-
-
-
-
Related Media
Archive-
18/11/2010
NanoViricides One2One Investor Presentation - 18th November 2010 (PDF)
NanoViricides One2One Investor Presentation - 18th November 2010
Presentations & Company Media
No documents available.
Related Research & Media
23/06/2011
Eugene Seymour interview (Audio/Video)
Company Statement:
The Company is a pre-clinical biotech company focused on an evolving $100B world-wide market. We are developing drugs aimed at the destruction of viruses in the body. The Company has drug candidates against nine different viruses. These are currently being studied in animals. These viruses include Ebola, Marburg, adenovirus and herpes simplex virus of the external eye, HIV, rabies, dengue and all influenza viruses. All of the drugs consist of a nanomicelle (a polymer-based 20nm lipophilic structure) that is attached to a ligand (receptor molecule). All that is needed to target a new virus is to change the ligand.
Management
CEO: Eugene Seymour, MD, MPH
Chairman and President : Anil R. Diwan, PhD
CSO: Randall Barton, PhD
CRO:Krishna Menon, VMD, PhD, MRCS
Contact Information
135 Wood Street
Suite. 205
West Haven, CT 06516
USA
Corporate Information
No info available.
